NovoCure (NVCR) Stock Forecast, Price & News

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

Is NovoCure a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NovoCure stock.
View analyst ratings for NovoCure or view top-rated stocks.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for NovoCure.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its earnings results on Thursday, April, 28th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.15. The medical equipment provider had revenue of $137.50 million for the quarter, compared to analyst estimates of $134.29 million. NovoCure had a negative trailing twelve-month return on equity of 14.21% and a negative net margin of 10.94%. The company's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.04) earnings per share.
View NovoCure's earnings history.

What price target have analysts set for NVCR?

8 Wall Street analysts have issued 1-year price objectives for NovoCure's shares. Their forecasts range from $70.00 to $250.00. On average, they anticipate NovoCure's share price to reach $144.75 in the next year. This suggests a possible upside of 80.5% from the stock's current price.
View analysts' price targets for NovoCure or view top-rated stocks among Wall Street analysts.

Who are NovoCure's key executives?

NovoCure's management team includes the following people:

• Mr. William F. Doyle, Exec. Chairman (Age 60, Pay $1.83M)
• Mr. Asaf Danziger, Pres, CEO & Director (Age 56, Pay $2.01M)
• Ms. Ashley Cordova, Chief Financial Officer (Age 42, Pay $995.2k) (LinkedIn Profile)
• Mr. Wilhelmus C. M. Groenhuysen, Chief Operating Officer (Age 64, Pay $1.44M)
• Mr. Pritesh Shah, Chief Commercial Officer (Age 44, Pay $946.17k) (LinkedIn Profile)
• Prof. Yoram Palti M.D., Ph.D., Founder & CTO (Age 84)
• Ms. Ingrid Goldberg, VP of Investor Relations
• Mr. Barak Ben Arye, Gen. Counsel
• Mr. William Patrick Burke, Chief HR Officer (Age 67)
• Dr. Ely Benaim M.D., Chief Medical Officer (Age 61)

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

Who are some of NovoCure's key competitors?

Some companies that are related to NovoCure include ResMed (RMD), DexCom (DXCM), Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), Globus Medical (GMED), ShockWave Medical (SWAV), Penumbra (PEN), Integra LifeSciences (IART), Inspire Medical Systems (INSP), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), iRhythm Technologies (IRTC) and Merit Medical Systems (MMSI).
View all of NVCR's competitors.

What other stocks do shareholders of NovoCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Square (SQ).

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by many different retail and institutional investors. Top institutional investors include Capital World Investors (12.10%), Capital International Investors (10.85%), Baillie Gifford & Co. (8.93%), Vanguard Group Inc. (7.65%), BlackRock Inc. (6.44%) and Deep Track Capital LP (0.96%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure.

Which institutional investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Compagnie Lombard Odier SCmA, Zurcher Kantonalbank Zurich Cantonalbank , KBC Group NV, Baillie Gifford & Co., Banque Pictet & Cie SA, Citigroup Inc., and Russell Investments Group Ltd.. Company insiders that have sold NovoCure company stock in the last year include Ashley Cordova, Ely Benaim, Frank X Leonard, Gabriel Leung, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure or view top insider-selling stocks.

Which institutional investors are buying NovoCure stock?

NVCR stock was purchased by a variety of institutional investors in the last quarter, including Deep Track Capital LP, Sumitomo Mitsui Trust Holdings Inc., Wolverine Asset Management LLC, Vanguard Group Inc., JPMorgan Chase & Co., Clearbridge Investments LLC, Frontier Capital Management Co. LLC, and C WorldWide Group Holding A S.
View insider buying and selling activity for NovoCure or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $80.19.

How much money does NovoCure make?

NovoCure has a market capitalization of $8.39 billion and generates $535.03 million in revenue each year. The medical equipment provider earns $-58.35 million in net income (profit) each year or ($0.560010) on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 1,167 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 441534756700 or via email at [email protected].